Page last updated: 2024-09-04

pumosetrag and Gastroesophageal Reflux

pumosetrag has been researched along with Gastroesophageal Reflux in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Choung, RS; Crowell, MD; Devault, K; Francis, DD; Harmsen, WS; Katzka, D; Locke, GR; Orr, WC; Talley, NJ; Winkle, PJ; Zinsmeister, AR	1
Evangelista, S	1
Choung, RS; Dierkhising, RA; Ferguson, DD; Kammer, PP; Landau, SB; Murray, JA; Nurbhai, S; Talley, NJ; Zinsmeister, AR	1

Reviews

1 review(s) available for pumosetrag and Gastroesophageal Reflux

Article	Year
Drug evaluation: Pumosetrag for the treatment of irritable bowel syndrome and gastroesophageal reflux disease. Current opinion in investigational drugs (London, England : 2000), 2007, Volume: 8, Issue:5 Topics: Animals; Dopamine Agents; Gastroesophageal Reflux; Gastrointestinal Agents; Humans; Irritable Bowel Syndrome; Pyridines; Quinuclidines; Receptors, Serotonin, 5-HT3; Treatment Outcome	2007

Trials

2 trial(s) available for pumosetrag and Gastroesophageal Reflux

Article	Year
Novel partial 5HT3 agonist pumosetrag reduces acid reflux events in uninvestigated GERD patients after a standard refluxogenic meal: a randomized, double-blind, placebo-controlled pharmacodynamic study. Neurogastroenterology and motility, 2014, Volume: 26, Issue:1 Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Drug Partial Agonism; Female; Gastroesophageal Reflux; Heartburn; Humans; Male; Meals; Middle Aged; Pyridines; Quinuclidines; Serotonin 5-HT3 Receptor Agonists; Young Adult	2014
A novel partial 5HT3 agonist DDP733 after a standard refluxogenic meal reduces reflux events: a randomized, double-blind, placebo-controlled pharmacodynamic study. Alimentary pharmacology & therapeutics, 2008, Mar-01, Volume: 27, Issue:5 Topics: Adolescent; Adult; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Tolerance; Electric Impedance; Female; Food; Gastroesophageal Reflux; Gastrointestinal Agents; Humans; Hydrogen-Ion Concentration; Male; Manometry; Middle Aged; Pyridines; Serotonin Receptor Agonists	2008

Article

Year

Novel partial 5HT3 agonist pumosetrag reduces acid reflux events in uninvestigated GERD patients after a standard refluxogenic meal: a randomized, double-blind, placebo-controlled pharmacodynamic study.

Neurogastroenterology and motility, 2014, Volume: 26, Issue:1

Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Drug Partial Agonism; Female; Gastroesophageal Reflux; Heartburn; Humans; Male; Meals; Middle Aged; Pyridines; Quinuclidines; Serotonin 5-HT3 Receptor Agonists; Young Adult

2014

A novel partial 5HT3 agonist DDP733 after a standard refluxogenic meal reduces reflux events: a randomized, double-blind, placebo-controlled pharmacodynamic study.

Alimentary pharmacology & therapeutics, 2008, Mar-01, Volume: 27, Issue:5

Topics: Adolescent; Adult; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Tolerance; Electric Impedance; Female; Food; Gastroesophageal Reflux; Gastrointestinal Agents; Humans; Hydrogen-Ion Concentration; Male; Manometry; Middle Aged; Pyridines; Serotonin Receptor Agonists

2008